Home › Funds › BROADWOOD CAPITAL INC › LCTX
BROADWOOD CAPITAL INC position in LCTX
LINEAGE CELL THERAPEUTICS IN · Health Care
BROADWOOD CAPITAL INC reported holding 49,560,992 shares of LCTX (LINEAGE CELL THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$47.4M, representing 3.04% of its reported portfolio and ranking #5 among its reported holdings. BROADWOOD CAPITAL INC has disclosed LCTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How BROADWOOD CAPITAL INC's LCTX position evolved
BROADWOOD CAPITAL INC first disclosed a stake in LCTX in Q3 2023 at 34,935,485 shares (US$41.2M). The position peaked in Q3 2025 at 49,560,992 shares, worth US$83.8M. Across 13 filings, BROADWOOD CAPITAL INC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 49,560,992 shares valued at US$47.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 34.94M | $41.22M | New |
| Q4 2023 | 34.94M | $38.08M | Hold |
| Q1 2024 | 41.67M | $61.67M | Add |
| Q2 2024 | 41.67M | $41.55M | Hold |
| Q3 2024 | 41.67M | $37.72M | Hold |
| Q4 2024 | 41.67M | $20.94M | Hold |
| Q1 2025 | 49.56M | $22.38M | Add |
| Q2 2025 | 49.56M | $44.97M | Hold |
| Q3 2025 | 49.56M | $83.76M | Hold |
| Q4 2025 | 49.56M | $82.77M | Hold |
| Q1 2026 | 49.56M | $78.31M | Hold |
| Q2 2026 | 49.56M | $64.92M | Hold |
| Q3 2026 | 49.56M | $47.37M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LCTX and 13F data
LCTX (LINEAGE CELL THERAPEUTICS IN) is a Health Care company. 28 other funds we track also report a position in LCTX — the largest reported positions include Defender Capital, LLC. (US$6.4M), RAFFLES ASSOCIATES LP (US$5.0M), Connective Capital Management, LLC (US$281K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LCTX
- Defender Capital, LLC. 6.65M sh · $6.35M · Q3 2026
- RAFFLES ASSOCIATES LP 5.20M sh · $4.97M · Q3 2026
- Connective Capital Management, LLC 293.62K sh · $280.62K · Q3 2026
More on BROADWOOD CAPITAL INC
FAQ
How long has BROADWOOD CAPITAL INC held LCTX?
BROADWOOD CAPITAL INC has disclosed LCTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is BROADWOOD CAPITAL INC's current position in LCTX?
As of Q3 2026, BROADWOOD CAPITAL INC holds 49.56M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $47.37M, representing 3.04% of its reported portfolio and ranking #5.
Has BROADWOOD CAPITAL INC been buying or selling LCTX?
In the latest 13F filing (Q3 2026), BROADWOOD CAPITAL INC held unchanged its position in LCTX. The position peaked in Q3 2025 at 49.56M shares.
Which other funds hold LCTX?
Other major institutional holders of LCTX include Defender Capital, LLC., RAFFLES ASSOCIATES LP, Connective Capital Management, LLC, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.